American Century Companies Inc. Boosts Stake in Innoviva, Inc.

Investment firm increases holding in biotech company by 13.8% in third quarter

Published on Mar. 7, 2026

Got story updates? Submit your updates here. ›

American Century Companies Inc. grew its position in Innoviva, Inc. (NASDAQ:INVA) by 13.8% in the third quarter, according to a recent SEC filing. The firm now owns 2,351,006 shares of the biotechnology company's stock, representing approximately 3.73% ownership.

Why it matters

This transaction highlights the continued institutional investor interest in Innoviva, a biotech company focused on respiratory therapies. The increased stake by American Century suggests they see long-term value in Innoviva's portfolio and royalty-based business model.

The details

According to the filing, American Century purchased an additional 284,253 shares of Innoviva during the third quarter, bringing their total holding to over 2.3 million shares. Innoviva is a biotech company that primarily generates revenue through royalties on respiratory treatments developed by its former affiliate and now marketed by GlaxoSmithKline.

  • The SEC filing was made on March 7, 2026, covering activity in the third quarter of the previous year.

The players

American Century Companies Inc.

An investment management firm that oversees over $200 billion in assets.

Innoviva, Inc.

A biotech company that focuses on acquiring and monetizing royalty interests in respiratory therapies.

Got photos? Submit your photos here. ›

The takeaway

This transaction demonstrates the continued institutional confidence in Innoviva's business model and growth potential, as a major investment firm has increased its stake in the company by a significant margin.